Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

J C Jones

Showing results (231-240 of 243) with videos related to

Pageof 25
Sort By:
Breast Cancer Research and Treatment|January 1, 1982
Estrogen receptor status as a prognostic indicator for stage I breast cancer patientsJ P Crowe, C A Hubay, O H Pearson, et al.
Breast Cancer Research and Treatment|January 1, 1983
Adjuvant endocrine therapy, cytotoxic chemotherapy, and immunotherapy in stage-II breast cancer: five-year resultsO H Pearson, C A Hubay, J S Marshall, et al.
Proceedings of the National Academy of Sciences of the United States of America|May 17, 2000
The ADP ribosylation factor nucleotide exchange factor ARNO promotes beta-arrestin release necessary for luteinizing hormone/choriogonadotropin receptor desensitizationS Mukherjee, V V Gurevich, J C Jones, et al.
The Journal of Biological Chemistry|August 11, 2001
Follicle-stimulating hormone stimulates protein kinase A-mediated histone H3 phosphorylation and acetylation leading to select gene activation in ovarian granulosa cellsL M Salvador, Y Park, J Cottom, et al.
Current Surgery|January 1, 1984
The prognostic importance of estrogen receptor level for Stage I breast cancer patientsJ P Crowe, N H Gordon, C A Hubay, et al.
Surgery|July 1, 1984
Antiestrogen-cytotoxic chemotherapy and bacillus Calmette-Guerin vaccination in stage II breast cancer: seventy-two-month follow-upC A Hubay, N H Gordon, J P Crowe, et al.
DNA and Cell Biology|July 6, 2000
Imidazoline receptor antisera-selected (IRAS) cDNA: cloning and characterizationJ E Piletz, T R Ivanov, J D Sharp, et al.
European Journal of Cancer|January 1, 1980
Adjuvant chemotherapy, anti-estrogen therapy and immunotherapy for stage II breast cancerC A Hubay, O H Pearson, J S Marshall, et al.
Surgery|May 1, 1980
Antiestrogen, cytotoxic chemotherapy, and bacillus Calmette-Guerin vaccination in stage II breast cancer: a preliminary reportC A Hubay, O H Pearson, J S Marshall, et al.
Cancer|December 15, 1980
Adjuvant chemotherapy, antiestrogen therapy and immunotherapy for stage II breast cancer: 45-month follow-up of a prospective, randomized clinical trialC A Hubay, O H Pearson, J S Marshall, et al.
Pageof 25

Showing results (231-240 of 243) with videos related to

Sort By:
Pageof 25
Breast Cancer Research and Treatment|January 1, 1982
Estrogen receptor status as a prognostic indicator for stage I breast cancer patientsJ P Crowe, C A Hubay, O H Pearson, et al.
Breast Cancer Research and Treatment|January 1, 1983
Adjuvant endocrine therapy, cytotoxic chemotherapy, and immunotherapy in stage-II breast cancer: five-year resultsO H Pearson, C A Hubay, J S Marshall, et al.
Proceedings of the National Academy of Sciences of the United States of America|May 17, 2000
The ADP ribosylation factor nucleotide exchange factor ARNO promotes beta-arrestin release necessary for luteinizing hormone/choriogonadotropin receptor desensitizationS Mukherjee, V V Gurevich, J C Jones, et al.
The Journal of Biological Chemistry|August 11, 2001
Follicle-stimulating hormone stimulates protein kinase A-mediated histone H3 phosphorylation and acetylation leading to select gene activation in ovarian granulosa cellsL M Salvador, Y Park, J Cottom, et al.
Current Surgery|January 1, 1984
The prognostic importance of estrogen receptor level for Stage I breast cancer patientsJ P Crowe, N H Gordon, C A Hubay, et al.
Surgery|July 1, 1984
Antiestrogen-cytotoxic chemotherapy and bacillus Calmette-Guerin vaccination in stage II breast cancer: seventy-two-month follow-upC A Hubay, N H Gordon, J P Crowe, et al.
DNA and Cell Biology|July 6, 2000
Imidazoline receptor antisera-selected (IRAS) cDNA: cloning and characterizationJ E Piletz, T R Ivanov, J D Sharp, et al.
European Journal of Cancer|January 1, 1980
Adjuvant chemotherapy, anti-estrogen therapy and immunotherapy for stage II breast cancerC A Hubay, O H Pearson, J S Marshall, et al.
Surgery|May 1, 1980
Antiestrogen, cytotoxic chemotherapy, and bacillus Calmette-Guerin vaccination in stage II breast cancer: a preliminary reportC A Hubay, O H Pearson, J S Marshall, et al.
Cancer|December 15, 1980
Adjuvant chemotherapy, antiestrogen therapy and immunotherapy for stage II breast cancer: 45-month follow-up of a prospective, randomized clinical trialC A Hubay, O H Pearson, J S Marshall, et al.
Pageof 25